C4 therapeutics reports second quarter 2023 financial results and recent business highlights

Established exclusive licensing agreement for cft8919, an egfr l858r bidac™ degrader, with betta pharmaceuticals in greater china for nsclc; u.s. ind cleared

CCCC Ratings Summary

CCCC Quant Ranking